EXELIXIS INC. for EXELIXIS INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 20, 2026 | $500,000 | Replaced |
| 4th Quarter - Amendment | Jan 20, 2026 | $510,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
IRC Section 174 amortization of R&D expenditures.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES M. FENTON | — |
| ERIN HERMANCE | — |
| JARED DANIEL MICHAUD | — |
Health Issues HCR
Proposals related to drug pricing including the Administrations Most-Favored-Nation Prescription Drug Pricing proposal, implementation of drug-related provisions of the Inflation Reduction Act, and administration of the 340B Drug Pricing Program. PBM reform proposals. The Help Ensure Lower Patient (HELP) Copays Act. Intellectual property proposals relating to life sciences. S.1930/HR 3731, Small Biotech Innovation Act. Health agency funding levels.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES M. FENTON | — |
| ERIN HERMANCE | — |
| JARED DANIEL MICHAUD | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.